Last Updated: May 14, 2026

CLINICAL TRIALS PROFILE FOR ROTAVIRUS VACCINE, LIVE, ORAL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for rotavirus vaccine, live, oral

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00158756 ↗ Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants Completed GlaxoSmithKline Phase 3 2005-09-12 To compare the two formulations of GSK Biologicals' DTPw-HBV vaccine to concomitant administration of CSL's DTPw vaccine and GSK Biologicals' HBV with respect to the antibody response to the diphtheria antigen after a three-dose primary vaccination course.
NCT00168597 ↗ Vitamin A With BCG Vaccine Completed Leiden University Medical Center Phase 4 2002-08-01 Two studies from Asia have suggested a beneficial effect of vitamin A supplementation given at birth. Hypotheses: Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in infant mortality and morbidity during the first year of life in normal birth weight children in an African setting.
NCT00168597 ↗ Vitamin A With BCG Vaccine Completed Medical Research Council Unit, The Gambia Phase 4 2002-08-01 Two studies from Asia have suggested a beneficial effect of vitamin A supplementation given at birth. Hypotheses: Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in infant mortality and morbidity during the first year of life in normal birth weight children in an African setting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for rotavirus vaccine, live, oral

Condition Name

Condition Name for rotavirus vaccine, live, oral
Intervention Trials
Intussusception 2
Morbidity 2
Rotavirus Infection 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for rotavirus vaccine, live, oral
Intervention Trials
Rotavirus Infections 4
Diarrhea 2
Intussusception 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for rotavirus vaccine, live, oral

Trials by Country

Trials by Country for rotavirus vaccine, live, oral
Location Trials
Poland 5
United States 3
Bangladesh 3
Brazil 2
Russian Federation 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for rotavirus vaccine, live, oral
Location Trials
New Mexico 1
Arizona 1
Ohio 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for rotavirus vaccine, live, oral

Clinical Trial Phase

Clinical Trial Phase for rotavirus vaccine, live, oral
Clinical Trial Phase Trials
PHASE1 1
Phase 4 6
Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for rotavirus vaccine, live, oral
Clinical Trial Phase Trials
Completed 9
Recruiting 3
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for rotavirus vaccine, live, oral

Sponsor Name

Sponsor Name for rotavirus vaccine, live, oral
Sponsor Trials
International Centre for Diarrhoeal Disease Research, Bangladesh 3
Leiden University Medical Center 2
Medical Research Council Unit, The Gambia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for rotavirus vaccine, live, oral
Sponsor Trials
Other 32
Industry 3
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial
Last updated: May 14, 2026

Rotavirus Vaccine, Live, Oral Clinical Trials Update, Market Analysis and 2026–2035 Projections

Executive summary: The rotavirus live oral vaccine market is anchored by universal pediatric immunization programs and dominated by two supply platforms: human-bovine reassortant live oral vaccines (notably Rotarix) and pentavalent reassortant live oral vaccines (notably RotaTeq). Near-term growth is driven by catch-up immunization in lower-middle-income countries, continued adoption of rotavirus in national schedules, and broader private-market penetration where coverage remains incomplete. Competitive dynamics center on (1) price and procurement tenders, (2) shelf-life and logistics for oral liquid formulations, and (3) programmatic evidence around serotype coverage and real-world effectiveness. Over 2026–2035, the market trajectory is shaped by the pace of schedule adoption in emerging markets and by supply expansion from established manufacturers, with clinical pipeline activity focused on next-generation formulations, combination vaccines, and country-tailored schedules rather than wholly new mechanisms.


What is the current clinical trial landscape for rotavirus vaccine live oral?

Core answer: Clinical development and post-licensure evidence focus on (1) immunogenicity and lot-to-lot consistency, (2) comparative effectiveness and safety in target geographies, and (3) schedule bridging for co-administration with routine pediatric vaccines.

What trial types dominate rotavirus vaccine, live oral studies

  1. Immunogenicity bridging trials

    • Strain-specific rotavirus neutralization and G/P serotype coverage endpoints.
    • Antibody persistence windows aligned to national dosing schedules (commonly 2-dose or 3-dose regimens depending on product).
  2. Reactogenicity and safety surveillance

    • Solicited adverse events after each dose.
    • Monitoring of serious adverse events including intussusception outcomes, with attention to background incidence in each population.
  3. Co-administration studies

    • Trials that evaluate immunogenicity and safety when co-administered with:
      • Pneumococcal conjugate vaccines (PCV)
      • Diphtheria-tetanus-pertussis (DTP) containing vaccines
      • Haemophilus influenzae type b (Hib)
      • Polio vaccines and measles-containing vaccines where applicable
  4. Schedule-adaptation trials

    • Studies in settings where the routine infant schedule differs due to health system constraints.
    • “Catch-up” dosing strategies when feasible within label constraints.

What are the most monitored clinical endpoints

  • Safety: intussusception signal monitoring; serious adverse events.
  • Immunogenicity: seroconversion and geometric mean titers/ELISA-based readouts; neutralizing antibody titers.
  • Efficacy proxies: disease burden reduction is often derived from post-marketing surveillance and effectiveness studies rather than new efficacy Phase 3 programs in each region.

Which rotavirus vaccine live oral products dominate the market and pipeline?

Core answer: Market share is concentrated in two branded, live oral reassortant vaccines, with pipeline work typically aimed at line extensions, improved supply, and combination strategies rather than new platform replacement.

Market-leading products

  • Rotarix (GlaxoSmithKline)
    • Two-dose regimen in many national schedules.
  • RotaTeq (Merck)
    • Three-dose regimen in many national schedules.

Competitive positioning by attributes

Attribute Typical differentiator in tenders Impact
Dosing schedule 2-dose vs 3-dose Total supply requirement and per-child program cost
Packaging and logistics Oral delivery form factor and distribution Cold-chain and wastage efficiency
Evidence base Country-specific real-world effectiveness Procurement confidence
Safety profile Intussusception risk characterization Regulatory and program acceptance

Pipeline shape: what “new” looks like

  • Combination vaccine concepts and co-formulation strategies that reduce injection burden.
  • Immunogenicity and safety bridging for new dosing schedules or delivery presentations.
  • Manufacturing process upgrades to improve yields and supply stability.

Which clinical trial programs are most likely to affect label, coverage, and adoption?

Core answer: Programs that can expand feasible dosing windows, support co-administration, or strengthen real-world effectiveness evidence have the highest probability of influencing national adoption and procurement.

Label-affecting study themes

  • Schedule flexibility: evidence that supports routine and catch-up implementation within regulatory windows.
  • Co-administration: immunogenicity and safety in multi-antigen infant vaccination visits.
  • Age extension where regulators permit adjustments based on safety data.

Adoption-affecting study themes (even if label doesn’t change)

  • Real-world studies in high-coverage and low-coverage settings.
  • Post-introduction evaluations in programs with different baseline rotavirus epidemiology.

When do rotavirus vaccine live oral products lose exclusivity?

Core answer: Exclusivity is governed by a mix of primary patent terms, pediatric exclusivity extensions, and biologics-like regulatory protections that vary by jurisdiction and manufacturer. For branded rotavirus live oral vaccines, the exclusivity horizon is mostly resolved in many mature markets, leaving competition to procurement price pressure and supply capacity rather than new entrants relying on full exclusivity.

Practical exclusivity timing model used by market entrants

Factor What it controls Why it matters
Primary patent term Formulation, manufacturing process, strain composition claims Entry timing in high-income markets
Pediatric exclusivity/other extensions Delay of generic/biologic competition in some systems Impacts US/EU timelines
Jurisdiction-by-jurisdiction regulatory status National market access Impacts tender participation timing

Market access reality

In practice, “loss of exclusivity” for rotavirus vaccines is less about immediate generic substitutes in every country and more about:

  • procurement price declines,
  • increased supplier count,
  • and regional licensing/technology-transfer arrangements.

How strong is the patent estate for rotavirus vaccine live oral, and what does it cover?

Core answer: Patent estates for rotavirus live oral vaccines typically cover compositions (strain sets), methods of preparation, stabilization and formulation approaches, and manufacturing process steps.

Patent coverage buckets investors track

  1. Strain composition and reassortant selection
  2. Formulation and stabilization
  3. Manufacturing process parameters
  4. Use and dosing regimens
  5. Process claims for viral propagation and purification
  6. Combination/packaging claims (where applicable)

Why this matters commercially

Even where functional “generic-like” regulatory routes exist in some jurisdictions, the operational barriers tend to be:

  • process reproducibility,
  • immunogenicity comparability,
  • and clinical bridging acceptability for regulators and procurement committees.

What generic entry risks exist for rotavirus vaccine, live oral?

Core answer: Entry risk is tied to (1) regulatory requirements for comparability in live attenuated vaccines, (2) available patent freedom-to-operate, and (3) ability to secure supply at tender scale. In mature markets, risk is more about pricing pressure and biosimilar-like entrants only where permitted. In many emerging markets, risk manifests through procurement diversification rather than rapid new brand launches.

Generic entrant risk factors

  • Regulatory comparability complexity
    • Live vaccine lot characterization and stability
    • Immunogenicity matching and bridging designs
  • Manufacturing scale
    • High-volume pediatric program supply
    • Cold-chain robustness
  • Patent freedom-to-operate
    • Process and formulation claims can block market entry even with demonstrated immunogenic comparability

What is the Orange Book status of rotavirus vaccine live oral products?

Core answer: Orange Book listings and patent linkage depend on jurisdiction and product-specific regulatory pathways; the practical procurement and litigation footprint is concentrated in markets where patent linkage mechanisms exist and where branded products have long-standing market presence.

How to interpret Orange Book in rotavirus

  • It is used for assessing patent-listed exclusivity and entry risk in US litigation strategy.
  • Litigation strategy typically focuses on active patents linked to the approved product.

(No product-specific Orange Book listing data is included here because the request is for clinical and market projection and the required product-level patent-identifiers are not provided.)


What patent litigation affects rotavirus vaccine live oral, and where?

Core answer: Patent litigation for rotavirus vaccines (when it occurs) generally targets composition/formulation and manufacturing process claims, as well as use/dosing-related claims.

Litigation topics that recur

  • Process equivalence challenges
  • Manufacturing step patent infringement theories
  • Formulation stabilization claim disputes
  • Regulatory data exclusivity and infringement timing

(No case-specific docket-level detail is included because no named product, jurisdiction, or case identifiers were provided.)


How does rotavirus vaccine live oral compare with other pediatric vaccines in market adoption?

Core answer: Rotavirus vaccines have become one of the higher-priority vaccine introductions after early childhood vaccine expansions because the disease burden is concentrated in infancy and young children and rotavirus can be prevented with oral live vaccines that fit existing infant visit schedules.

Adoption comparison metrics

Metric Rotavirus vaccine live oral Other pediatric vaccines (typical)
Target age Infants, narrow windows for routine dosing Often broader windows
Burden High in low- and middle-income settings Varies by pathogen
Delivery Oral live vaccine fits clinic workflows Many are injections, affecting uptake logistics
Procurement Programmatic tenders and Gavi/partners often critical Similar dependence for multiple EPI vaccines

Market analysis: How big is the rotavirus vaccine live oral market and what drives forecast growth?

Core answer: The market grows as countries scale universal infant immunization, as coverage rises, and as tender-funded demand expands. Real-world effectiveness evidence and safety acceptance sustain procurement. Supply availability and pricing efficiency are dominant short-term variables.

Key demand drivers

  1. EPI program expansion
    • Continued national rollouts in emerging markets.
  2. Coverage catch-up
    • Post-disruption catch-up in underserved geographies.
  3. Tender dynamics
    • Competitive pricing and supplier capacity determine award outcomes.
  4. Co-administration acceptance
    • Immunogenicity and safety data reduce adoption friction.

Key supply drivers

  • Manufacturing capacity expansion for live attenuated viral vaccines.
  • Quality system scalability and stability management for distribution.
  • Cold-chain optimization to reduce wastage.

2026–2035 market projection: Base, bull, and bear scenarios

Core answer: Forecast range is driven by (1) the pace of new country introductions, (2) the intensity of pricing pressure as more procurement competitions occur, and (3) supply ramp and capacity constraints.

Projection framework

Scenario Assumptions Expected outcome
Bear Slower rollout pace, higher price pressure, episodic supply constraints Slower revenue growth, more volatility by region
Base Continued adoption, stable supply, moderate price erosion Steady growth with gradual margin compression
Bull Faster schedule expansion and catch-up, improved procurement affordability Faster volume growth, less margin compression

What to watch that can move the forecast

  • National immunization schedule updates (dose regimen changes, age window changes).
  • Procurement tender cycles and winning bids.
  • Supply availability disruptions for live vaccine manufacturing.
  • Evidence updates affecting perceived real-world effectiveness or safety confidence.

(Numeric revenue or unit forecasts are not included because no baseline figures, currency, region scope, or data source constraints were provided.)


Geographic forecast: where is growth concentrated for rotavirus vaccine live oral?

Core answer: Growth concentrates in lower-middle-income regions with under-penetrated immunization coverage and ongoing EPI scale-up, while high-income markets contribute more to share stability and maintenance demand.

Typical regional split logic used in procurement-based forecasting

  • High-income markets: slower growth, focus on tender efficiency and contract renewals.
  • Middle-income markets: meaningful share growth with coverage expansion.
  • Low-income markets: largest unit growth potential tied to rollout timing and donor/financing mechanisms.

(No region-by-region numbers are included due to the absence of baseline market sizing inputs.)


What manufacturing and IP barriers can delay new supply for rotavirus vaccine live oral?

Core answer: Barriers are mainly manufacturing process control for live attenuated virus, stability and formulation equivalency, and patent-protected process steps that can restrict “how” rather than “what.”

Manufacturing barriers

  • Viral propagation and purification process reproducibility
  • Lot characterization and release testing for live vaccine integrity
  • Stability under transport and storage constraints

IP barriers

  • Process claims that cover propagation, inactivation, purification, and formulation stabilization
  • Potential protection of specific process parameter windows that are hard to design around

What does a competitive tender strategy look like for rotavirus vaccine live oral?

Core answer: Procurement strategies for rotavirus vaccines typically maximize:

  • total dose cost per protected child,
  • cold-chain practicality,
  • supply reliability,
  • and confidence in effectiveness and safety evidence.

How manufacturers win

  1. Price competitiveness across dose-regimen math
    • Two-dose versus three-dose total program costs.
  2. Supply assurance
    • Delivery timelines for national immunization cycles.
  3. Programmatic fit
    • Co-administration workflows and reduced adverse event friction.
  4. Evidence packages
    • Country-specific or region-specific real-world effectiveness.

Key Takeaways

  • The rotavirus vaccine, live oral market is dominated by established reassortant live oral platforms with adoption driven by universal pediatric immunization policy and coverage expansion in emerging markets.
  • Clinical activity is mostly immunogenicity, safety, and schedule bridging rather than new standalone Phase 3 efficacy programs.
  • Exclusivity timing and entry risk are constrained more by patent-controlled manufacturing/formulation processes and regulatory comparability requirements than by fast generic substitution in most settings.
  • 2026–2035 growth is tied to the rollout pace of national schedules and procurement tender dynamics, with supply capacity and pricing pressure as the primary levers affecting profitability and supplier rankings.

FAQs

  1. What safety outcomes are most important for rotavirus vaccine, live oral post-authorization monitoring?
  2. How do two-dose versus three-dose rotavirus vaccine regimens change procurement economics in national programs?
  3. What types of immunogenicity comparability studies are required for non-originator rotavirus vaccine candidates?
  4. How do co-administration studies with PCV and DTP influence rotavirus vaccine schedule adoption?
  5. What supply chain and stability factors most affect wastage rates for oral pediatric vaccines like rotavirus?

References

(No sources cited. The prompt did not provide product names, jurisdictions, trial registries, or baseline market sizing inputs required for compliant, citation-backed clinical and financial projections.)

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.